Introduction {#sec1-1}
============

Phagocytic and antigen-presenting cells of the innate immune system such as macrophages or dendritic cells immediately recognize invasive microorganisms, which are able to overcome anatomic host barriers such as epithelial surfaces and enter the organism. The undisturbed function of phagocytes in this first line of host defense is pivotal for a successful immune response towards infection.

The effective eradication of pathogens is underlain by several signaling events such as Toll-like-receptor (TLR) signaling; many of these are regulated in a miRNA-dependent manner \[[@ref1]\]. MicroRNAs (miRNAs) are small noncoding RNAs, which negatively influence gene expression by degradation of mRNA or inhibition of protein translation. MiRNA dysregulation in many cases leads to disease such as cancer or metabolic disorder. As a consequence, the use of miRNAs as a diagnostic tool and also the therapeutic application has become the major focus of investigation \[[@ref2]\]. The role of miRNAs in infectious diseases has become more and more apparent, and there are numerous reports about their involvement in viral and parasite infection. The contribution of miRNAs in bacterial diseases has been explored less. However, over the last years, several studies reported an increasing evidence of miRNA-mediated host response towards bacterial infection \[[@ref3], [@ref4]\]. Upon infection, miRNAs tightly control immune reactions, involving both miRNA-mediated unspecific cellular responses as well as pathogen-dependent regulation of a specific miRNA expression profile \[[@ref5]\].

Pathogenic species within the family of *Campylobacteraceae* belong to the leading causes for severe gastroenteritis worldwide. Within this family, *Arcobacter (A.) butzleri* is an emerging zoonotic pathogen and has recently been associated with cases of diarrhea, peritonitis, and bacteremia, but its relevance associated with disease still remains to be evaluated \[[@ref6]\]. Due to missing routine diagnostic and standardized isolation methods, the incidence of *A. butzleri*-associated diseases cannot be properly specified. Nevertheless, *Arcobacter* spp. are known to be the fourth most common pathogenic group isolated from stool specimens of patients with acute enteritis in several prevalence studies conducted in Europe \[[@ref7]\].

Understanding underlying regulatory mechanisms that occur in host cells upon *Arcobacter* infection is indispensable to evaluate the pathogenicity and to develop strategies to diagnose and combat *A. butzleri*-induced diseases. Thus, the aim of this study was to identify miRNAs expressed in innate immune cells in response to an *A. butzleri* infection. For that purpose, primary human macrophages were isolated from three different donors and infected with *A. butzleri.* Subsequent to infection, expression of miRNAs was studied by means of RNAseq.

Materials and methods {#sec1-2}
=====================

Bacterial strain and culture condition {#sec2-1}
--------------------------------------

*A. butzleri* reference strain CCUG30485 (Culture Collection University of Göteborg, Sweden) was cultivated and prepared for infection experiments as described previously \[[@ref10]\].

Isolation and cultivation of primary human macrophages {#sec2-2}
------------------------------------------------------

Buffy coats of healthy human donors were obtained at the German Red Cross in Berlin Wannsee. Blood mononuclear cells were isolated by Ficoll-Paque centrifugation and subsequent attachment to cell-culture flask surface. Cells were cultivated for 5 days in Gibco macrophage SFM medium including 10 μg/ml gentamycin (Biochrom) and 50 ng/ml M-CSF (PAN Biotech) (M-CSF stimulus was added for 2 days).

To determine the percentage of CD14+ cells in the isolated cell population, fluorescence-activated cell sorting (FACS) was performed using a FACSCalibur flow cytometer (Becton Dickinson GmbH). The CD14 antibody was purchased at Santa Cruz Biotechnology and used at a concentration of 1:100. The secondary antibody (IgG2a Goat Anti-Mouse, PE labeled, Southern Biotech) was used at 1:200.

If FACS analysis proved that the cell population contained more than 80% CD14+ cells, 6 × 10^5^ macrophages in 1.5 ml medium per well were seeded in six-well plates and used for infection experiments. Cells were incubated for another 24 h at 37 °C and 5% CO~2~ before further experimental use. Monocytes were isolated from three different human donors, and infection experiments were reproduced in three independent experimental setups.

Infection experiments {#sec2-3}
---------------------

Approximately 4--6 × 10^7^ bacterial cells were inoculated on 4--6 × 10^5^ primary human macrophages (multiplicity of infection \[MOI\] = 100) and incubated at 37 °C and 5% CO~2~. Noninfected cells served as a negative control. After 3 h of infection, cells were washed three times with phosphate-buffered solution (PBS) and incubated with fresh media containing 300 μg/ml gentamycin for another 2 h to remove remaining extracellular bacteria. Samples were taken 1 h, 5 h, and 24 h after infection. For the 24 h time point, cells were treated with 20 μg/ml gentamycin for the remaining incubation time. For RNA extraction, cells were washed three times with PBS, lysed with RNA lysis buffer (mirVANA, Life Technologies) and total RNA was isolated according to the manufacturer's instruction.

Quality control of isolated RNA {#sec2-4}
-------------------------------

Quantity and quality of RNA were first determined by measuring absorbance at 260 and 280 nm with a Nano Drop 1000 spectrophotometer according to the manufacturer's instructions (Thermo Scientific). Samples were further analyzed for their RNA integrity with an Agilent 2100 BioAnalyzer and RNA 6000 Nano Kits (Agilent) according to the manufacturer's protocol. RNA with integrity value (RIN) of ≥9 was used for further investigation.

RNAseq data analysis {#sec2-5}
--------------------

Sequencing of small RNA samples was performed at the Institute of Clinical Molecular Biology at Christian-Albrechts-University Kiel, Germany using a HiSeq2500 device (Illumina) as described earlier \[[@ref11]\].

The raw sequencing data were processed as described in detail in Leidinger et al.\[[@ref12]\]. In brief, we first trimmed the 3′ adapter sequence with the FastX toolkit. For quantification (mapping against miRBase release 20) and prediction of novel miRNAs (mapping against human genome hg19), the miRDeep2 pipeline was applied \[[@ref13]\]. We summarized the final read counts for known and novel miRNAs in an expression matrix and applied quantile normalization. For detecting deregulated miRNAs between different time points, we applied analysis of variance (ANOVA). For pair wise group comparisons, we applied two-tailed *t*-tests. All statistical calculations have been carried out using R version 3.0.2.

Pathway analysis {#sec2-6}
----------------

To unravel the role of differentially expressed miRNAs which have not yet been reported to play a role in bacterial infection, *in silico* prediction was used to identify mRNA targets (miRmap, miRmap score \<80) \[[@ref14]\]. The list of potential target genes was applied to the DAVID functional annotation tool \[[@ref15], [@ref16]\] to identify pathways in which these potential mRNA targets accumulate.

Validation of potential novel miRNAs {#sec2-7}
------------------------------------

Sequences of three potential novel miRNA candidates were selected from the sequencing results, and expression in macrophages upon infection was validated by means of miR-Q, a miRNA-specific reverse transcription quantitative polymerase chain reaction (RT-qPCR) \[[@ref17]\]. Oligonucleotides *([Table 1](#table001){ref-type="table"})* were designed and synthesized (Sigma-Aldrich), and miR-Q assays were performed as described earlier \[[@ref17]\] with an annealing temperature of 62 °C. Parallel to amplification of the potential novel miRNAs, reference small RNAs SNORD44 and SNORD47 were amplified and used for normalization. To determine specificity of amplified PCR products, melt curve analysis and electrophoresis were performed subsequent to amplification.

MiR-Q analysis {#sec2-8}
--------------

The ΔΔCT method \[[@ref18]\] was used to calculate the relative fold difference of miRNA expression levels compared to the negative control. To determine CT values, thresholds were set at 0.2.

Ethics {#sec2-9}
------

The local Ethics Commission at the Charité Berlin approved the study (EA1/092/14).

Results {#sec1-3}
=======

FACS analysis proves high efficiency of macrophage isolation and enrichment from human buffy coats {#sec2-10}
--------------------------------------------------------------------------------------------------

Since monocytes only represent a small fraction of leukocytes (2--6%), an enrichment step was necessary to obtain a high percentage of monocytes in the leukocyte cell composition. For this purpose, monocytes were isolated from buffy coats by density centrifugation and subsequent adherence to cell culture flasks in a differentiation medium. Subsequent to cultivation, flow cytometry was performed to analyze CD14 expression, a cell surface marker for monocytes and macrophages, and to reveal the purity of the isolated monocyte population. For that purpose, cells were stained with a CD14 antibody as well as a secondary fluorochrome-labeled antibody and analyzed with a cytometer. The fluorochrome-stained cells were gated and analyzed for CD14 antibody staining. Macrophage fraction in cell culture isolated and cultivated from Donor 1 constituted 97.02% *(Fig. S1, A)*; from Donor 2, 92.70% *(Fig. S1, B)*; and Donor 3, 81.0% *(Fig. S1, C).*

Sequencing and bioinformatic analysis reveal several miRNAs to be regulated upon A. butzleri infection {#sec2-11}
------------------------------------------------------------------------------------------------------

Since miRNAs were reported to exhibit rapid dynamics in their temporal expression in response to bacterial pathogens \[[@ref5], [@ref19]\], RNA samples of infected macrophages were investigated at three different time points to assess changes in miRNA patterns during the course of infection. An ANOVA analysis of the RNAseq data revealed 14 annotated human miRNAs, which were significantly regulated upon *A. butzleri* infection. An additional *t*-test displayed significant differences in expression levels compared to the noninfected control *([Table 2](#table002){ref-type="table"}).*

According to previous reports regarding regulatory functions of miRNAs, they could be grouped into miRNAs commonly affected by various bacterial agents and identified as key players in host innate immune response *([Fig. 1](#fig001){ref-type="fig"})* and those which have not been associated with bacterial diseases so far *([Fig. 2](#fig002){ref-type="fig"}).* Following this, differentially expressed miRNA in these two groups will be presented.

MiRNAs associated with bacterial infections {#sec2-12}
-------------------------------------------

MiR-125a, miR-155, miR-212, miR-181c, miR-21, miR-27a, let-7a, miR-26b, and miR-148b were differentially expressed in *A. butzleri*-infected human macrophages compared to the noninfected control and have previously been reported to play a role in host immune response towards bacterial infection *([Fig. 1](#fig001){ref-type="fig"}).* Expression levels of miR-125a-3p were increased in 5 h and 24 h *A. butzleri*-infected cells compared to respective controls. A continuous increase could be observed over the time of infection although slightly elevated expression levels were also found in 24 h noninfected cells. Significant differences were calculated for expression levels in 24 h infected samples versus the respective negative control (*p* \< 0.05). MiR-155-3p was significantly upregulated in infected macrophages 5 h postinfection (*p* \< 0.05). Twenty-four hours after infection, the expression level was similar to those of noninfected cells, whereas for miR-155-5p, expression level at 24 h remained significantly elevated (*p* \< 0.05). The expression level of neither miR-155-3p nor 5p was affected 1 h after infection. Overall, miR-155-5p was accumulated to a higher degree compared to miR-155-3p. MiR-212-3p was increased 24 h postinfection compared to the noninfected control as well as compared to the other time points of infection (*p* \< 0.05). Similar to miR-212-3p, miR-181c-5p as well as miR-21-3p was found to be upregulated 24 h after *A. butzleri* infection compared to other time points of infection. MiR-27a-5p showed an increased expression 1 h after infection compared to the noninfected control (*p* \< 0.05). MiRNA let-7a-3p (*p* \< 0.05) and miR-26b-5p decreased over the time of infection (*p* \< 0.05) whereas miR-148b-3p exhibited reduced expression levels 24 h after infection (*p* \< 0.05), and 1 h and 5 h after infection, expression was not affected. Highest miRNA copy numbers were found for miR-155-5p.

MiRNAs not yet associated with bacterial infections {#sec2-13}
---------------------------------------------------

MiR-3613, miR-2116, miR-671, miR-30d, and miR-629 exhibited significant differences in expression levels in infected macrophages. So far, none of these miRNAs have been described being commonly expressed in response to bacterial infection in human host cells.

As indicated in *[Fig. 2](#fig002){ref-type="fig"}*, miR-3613-5p exhibited elevated expression levels 5 h and 24 h postinfection compared to respective controls (*p* \< 0.05). Expression remained unaffected 1 h after infection. MiR-2116-3p and miR-671-3p were downregulated during infection 5 h and 24 h compared to respective controls (*p* \< 0.05). Expression of miR-30d-3p decreased over the time of infection; 5 h after infection, expression was significantly reduced compared to the noninfected control (*p* \< 0.05). Expression of miR-30d-5p exhibited a similar pattern as expression of miR-30d-3p did. Nevertheless, miR-30d-5p was accumulated to a much higher degree compared to miR-30d-3p. Expression of miR-629-5p was reduced 5 h after infection compared to noninfected cells (*p* \< 0.05).

To unravel the role of these miRNAs, *in silico* prediction was used to identify mRNA targets and pathways in which they accumulate. Beneath metabolic pathways, target accumulation was found for apoptosis/p53 signaling (targets of miR-3613 and miR-2116), MAPK signaling (targets of miR-671 and miR-30d-5p), endocytosis (targets of miR-30d-3p and 30d-5p), regulation of actin cytoskeleton (targets of miR-30d-3p), and formation of the immunoproteasome (targets of miR-629). The results are summarized in *[Table 3](#table003){ref-type="table"}.* Full data of the pathway analysis is attached in the supplementary data.

Potential novel human miRNAs {#sec2-14}
----------------------------

Raw data analysis indicated potential novel miRNAs, which have not yet been described. To follow up the expression of respective transcripts, primers were designed and expression in the same macrophage samples used for RNAseq was investigated by means of miRNA specific RT-qPCR (miR-Q). Fold induction of potential novel-miR-55 compared to the negative control increased over the time of infection; this was the case for both sequencing data *([Fig. 3](#fig003){ref-type="fig"})* and RT-qPCR analysis *([Fig. 4](#fig004){ref-type="fig"}).* However, sequencing data indicated a downregulation of novel-miR-55 in infected cells compared to respective negative controls, whereas in RT-qPCR data, novel-miR-55 was upregulated in infected cells. Transcript counts of potential novel-miRNAs in the analyzed samples are listed in *[Table 4](#table004){ref-type="table"}.* Potential novel-miR-134 was slightly upregulated 5 h and 24 h in RNAseq data *([Fig. 3](#fig003){ref-type="fig"}).* RT-qPCR indicated an upregulation in 24 h infected samples *([Fig. 4](#fig004){ref-type="fig"}).* Expression dynamics of potential novel-miR-259 correlated in comparing RNAseq and RT-qPCR analysis. Again, as described for novel-miR-55, RNAseq revealed a downregulation in infected cells *([Fig. 3](#fig003){ref-type="fig"})*, whereas RT-qPCR indicated an upregulation *([Fig. 4](#fig004){ref-type="fig"}).*

Discussion {#sec1-4}
==========

Several studies have shown that miRNAs are key regulators of innate immunity \[[@ref19]\] and play a prominent role in the specific host response towards bacterial pathogens \[[@ref22], [@ref23]\]. We have previously demonstrated that *A. butzleri* induce a pro-inflammatory response in human macrophages and have limited ability for intracellular survival \[[@ref10]\]. Since nothing is yet known about underlying regulatory mechanisms such as miRNA expression in response to infection, we challenged primary human macrophages with *A. butzleri* and analyzed miRNA expression by means of RNAseq.

Bioinformatic investigation of generated sequencing data revealed several miRNAs, which were differentially expressed in infected cells compared to the noninfected control. Some of these miRNAs have not yet been reported to play a role in the host response towards bacterial infection. However, most of the identified miRNAs belonged to a set of candidates, which were also expressed in immune cells in response to bacterial infection or LPS stimulus in previous studies (miR-155, miR-21, miR-125, miR-212, let-7a, miR-181c, miR-26b, miR-148a, and miR-27a) \[[@ref24]\].

Among these, miR-155, miR-21, miR-125, and let-7a play a central role in the immune response towards bacterial pathogens \[[@ref3], [@ref25]\]. They are mainly regulated in a Toll-like receptor dependent manner and, in turn, target different components of the TLR signaling cascade including TLRs themselves as well as downstream signaling proteins such as MyD88 and transcription factors such as NFκB as well as cytokines. MiRNAs can thereby control strength, location, and timing of TLR response \[[@ref19]\], which makes them crucial for a balanced immune homeostasis and protects the host from uncontrolled inflammatory conditions. Notably, expression of miR-146 did not display significant differences in *A. butzleri*-infected cells compared to the noninfected control, even though it is reported to act as a key regulator of TLR signaling in immune cells in response to various bacterial pathogens such as *Campylobacter concisus, Helicobacter pylori*, or *Salmonella enterica* \[[@ref4], [@ref29]\]. This might be due to expression dynamics in the course of infection. Nevertheless, in THP-1-derived macrophages infected with *C. concisus* (another member of the family of *Campylobacteraceae*), miR-146a was upregulated 6 h after infection \[[@ref29]\].

Interestingly, some differentially expressed miRNAs identified in macrophages in response to *A. butzleri* have not been reported yet as regulators of host response to infection (miR-3613, miR-2116, miR-671, miR-30d-3p, miR-30d-5p, and miR-629-5p). *In silico* analysis employing miRmap software and DAVID functional annotation tool revealed that potential targets of these miRNAs (besides putative targets in metabolism and cancer) were enriched in pathways such as apoptosis/DNA damage, MAPK signaling, endocytosis, regulation of actin cytoskeleton, and formation of the immunoproteasome. Except for miR-3613, all miRNAs that were not yet associated with bacterial infections were downregulated during *Arcobacter* challenge.

In case of apoptosis, possibly involved miR-2116 was downregulated 24 h after infection. MiRmap revealed the initiator caspase 8 as a potential target. Therefore, an increased caspase activity due to the loss of miRNA-inhibition leading to onset of apoptosis in the course of infection could be hypothesized. The induction of apoptosis in macrophages to enhance virulence has been shown for several bacterial pathogens such as *Salmonella* spp. or *Shigella flexneri* \[[@ref30]\] and could favor the establishment of *A. butzleri* infection by impairing phagocytosis and eradication by immune cells. The regulatory role of miRNAs in apoptosis is well known \[[@ref31]\], and the modulation of host miRNA expression to attenuate macrophage function has been demonstrated for pathogens such as *Mycobacterium avium* \[[@ref4], [@ref23]\]. Although we were able to demonstrate the initial activation of initiator as well as effector caspases in THP-1-derived macrophages in response to *A. butzleri* infection in a previous study \[[@ref10]\], DNA damage and end-point apoptosis could not be detected. However, this could be different in primary human macrophages and needs to be the matter of deeper investigations. In case of endocytosis, possibly involved miR-30d-3p and miR-30d-5p were downregulated in *A. butzleri*-challenged cells, suggesting a miRNA-mediated boost of endocytosis in response to *Arcobacter* infection.

In addition, three potential novel miRNAs (novel-miR-55, novel-miR-134, and novel-miR-259) were identified in *A. butzleri*-infected macrophages and expression was followed up by RT-qPCR. Nevertheless, further experiments are necessary to validate the expression of the novel miRNAs and their functional role.

Overall, the miRNA response of macrophages towards *A. butzleri* infection differed from recent findings regarding infection of THP-1 cells with *C. concisus* \[[@ref29]\]. There were no overlaps in miRNA expression in both studies underlining the observation that differences in expression levels and profiles depend on the stimulus and cell type \[[@ref19]\]. This study suggests that macrophage function is controlled by a specific set of miRNAs during *A. butzleri* infection. These miRNAs may not only constitute a potential therapeutic target but also function as promising diagnostic marker for the infection.
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MiRNAs associated with bacterial diseases, expressed in primary human macrophages as a response to *A. butzleri* infection. Cells were infected at a MOI of 100. Samples were taken 1 h, 5 h, and 24 h after infection (A.b. *= A. butzleri* reference strain CCUG30485, n.c. = noninfected cells). Asterisks in figures summarize *p* values (^\*^*p* \< 0.05; ^\*\*^*p* \< 0.01)
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![MiRNAs not yet associated with bacterial diseases, expressed in primary human macrophages as a response to *A. butzleri* infection. Cells were infected at a MOI of 100. Samples were taken 1 h, 5 h, and 24 h after infection. Asterisks in figures summarize *p* values (^\*^*p* \< 0.05; ^\*\*^*p* \< 0.01)](eujmi-06-099-g003){#fig002}

![RNA sequences were analyzed for potential novel miRNA sequences using mirDeep2 algorithms \[[@ref13]\]](eujmi-06-099-g004){#fig003}

![Expression of respective novel sequences in macrophage samples were followed up by means of RT-qPCR (miR-Q)](eujmi-06-099-g005){#fig004}

![FACS plots CD14, primary human macrophages. (A) FACS plot indicates 97.82% CD14+ of gated cells with 0.8% unspecific binding of the secondary antibody (IgG2a) isolated from Donor 1. (B) Isolated primary cells of Donor 2 yield 93.51% CD14+ cells minus 0.81% due to unspecific binding of the secondary antibody. (C) 81.45% CD14+ cells isolated from Donor 3 with 0.45% unspecific binding of the secondary antibody](eujmi-06-099-g006){#fig005}

###### 

Oligonucleotides used for validation of novel miRNAs

  Novel-miR                       Sequence (annealing temperature: 62 °C)
  ------------------------------- ---------------------------------------------------------
  RT6-novel-miR-259 5′-3′         **tgtcaggcaaccgtattcaccgtgagtggt**GCTAGA
  Short-novel-miR-259-rev 5′-3′   **cgtcagatgtccgagtagagggggaacggcg**CTCTGACCTCTGACCCTCT
  RT6-novel-miR-55 5′-3′          **tgtcaggcaaccgtattcaccgtgagtggt**TCTGCG
  Short-novel-miR-55-rev 5′-3′    **cgtcagatgtccgagtagagggggaacggcg**AGGGCCTGCTCCCACCCCGC
  RT-6-novel-miR-134 5′-3′        **tgtcaggcaaccgtattcaccgtgagtggt**AACTCT
  Short-novel-miR-134-rev 5′-3′   **cgtcagatgtccgagtagagggggaacggcg**AAAAGCTGTCCACTGTAGA
  cDNA                            
  Novel-miR-259 5′-3′             GCTAGAGGGTCAGAGGTCAGAG
  Novel-miR-55 5′-3′              TCTGCGGGGTGGGAGCAGGCCCT
  Novel-miR-134 5′-3′             AACTCTACAGTGGACAGCTTTT

###### 

MiRNAs found to be regulated upon *A. butzleri* infection

  miR         Sequence                  *p* value (different time points of infection compared to noninfected control)
  ----------- ------------------------- --------------------------------------------------------------------------------
  125a-3p     acaggugagguucuugggagcc    0.038 (24 h vs. n.c.)
  155-3p      cuccuacauauuagcauuaaca    0.035 (5 h vs. n.c.)
  155-5p      uuaaugcuaaucgugauaggggu   0.02 (5 h vs. n.c.)
  212-3p      uaacagucuccagucacggcc     0.034 (24 h vs. n.c.)
  181c-5p     aacauucaaccugucggugagu    0.034 (24 h vs. n.c.)
  21-3p       caacaccagucgaugggcugu     0.012 (24 h vs. n.c.)
  27a-5p      agggcuuagcugcuugugagca    0.049 (1 h vs. n.c.)
  let-7a-3p   cuauacaaucuacugucuuuc     0.05 (24 h vs. n.c.)
  26b-5p      uucaaguaauucaggauaggu     0.044 (1 h vs. n.c.), 0.048 (5 h vs. n.c.), 0.004 (24 h vs. n.c.)
  148b-3p     ucagugcacuacagaacuuugu    0.004 (24 h vs. n.c.)
  3613-5p     uguuguacuuuuuuuuuuguuc    0.018 (5 h vs. n.c.), 0.019 (24 h vs. n.c.)
  2116-3p     ccucccaugccaagaacuccc     0.025 (5 h vs. n.c.), 0.032 (24 h vs. n.c.)
  671-3p      uccgguucucagggcuccacc     0.003 (5 h vs. n.c.), 0.009 (24 h vs. n.c.)
  30d-3p      cuuucagucagauguuugcugc    0.038 (5 h vs. n.c.)
  30d-5p      uguaaacauccccgacuggaag    0.035 (24 h vs. n.c.)
  629-5p      uggguuuacguugggagaacu     0.03 (5 h vs. n.c.)

###### 

Pathways with enriched mRNA targets potentially influenced by *A. butzleri*-induced miRNAs

  Pathway                                                                    miRNAs                                                                          mRNA targets                                                                                                                                 *p* value
  -------------------------------------------------------------------------- ------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- -----------
  Endocytosis                                                                miR-30d-3p                                                                      SH3GL3, DNM3, FLT1, ERBB4, STAM2, VTA1, PRKCI, ARF6, HLA-B, KIT, ZFYVE20, RAB31, AP2B1, RAB11FIP2, CHMP1B, RAB22A, RAB11B, VPS36, RNF41      0.063
  miR-30d-5p                                                                 NEDD4, ACAP2, RAB11A, EEA1, NEDD4L, KIT, ARAP2, CHMP2B                          0.085                                                                                                                                        
  Apoptosis/p53 signaling pathway                                            miR-3613                                                                        CDK6, RRM2B, ATR, SESN3                                                                                                                      0.037
  miR-2116                                                                   IRAK2, IRAK1, IRAK3, PRKAR2A, DFFA, PIK3CB, CASP8, CHP2, EXOG, PPP3R2, PIK3R1   0.076                                                                                                                                        
  EI24, CD82, RRM2, SERPINE1, CASP8, RCHY1, RRM2B, MDM4, PERP, CDK2, SESN3   0.017                                                                                                                                                                                                                        
  Regulation of actin cytoskeleton                                           miR-30d-3p                                                                      GNA13, FGF7, PIK3CB, ROCK2, DIAPH2, SSH2, GNA12, ITGA1, ACTN2, PPP1CB, NCKAP1, DOCK1, CHRM2, TIAM1, SOS1, SOS2, WASL, CRK, FGF2, MYLK, APC   0.079
  MAPK signaling pathway                                                     miR-671                                                                         RASGRF1, FGF11, CACNB3, FGF1, CRK                                                                                                            0.063
  miR-30d-5p                                                                 MAP3K7, CASP3, MAP3K5, TAOK1, MAP3K2, PLA2G12A, NF1, PLA2G2C, PPP3CA, FGF20     0.099                                                                                                                                        
  Formation of immunoproteasome                                              miR-629                                                                         PSMA2, PSMB10, PSMD13, PSMB2, PSME4                                                                                                          0.023

###### 

Mean counts of potential novel-miRNA transcripts in infected cells (A.b.) and controls (n.c.) determined by RNAseq

  miRNA           A.b. 1 h   n.c. 1 h   A.b. 5 h   n.c. 5 h   A.b. 24 h   n.c. 24 h
  --------------- ---------- ---------- ---------- ---------- ----------- -----------
  Novel-miR-55    1.3        3.7        1.7        2.7        0.7         1.3
  Novel-miR-134   2          1.3        3.7        1.3        4           1.7
  Novel-miR-259   43.3       58         27         56         23          37

###### 

DAVID functional annotation list of *A. butzleri*-induced miRNAs and potentially influenced pathways

  miRNA                                          Pathway                           Count   *p* value                                                                                                                                                                                                     Genes                                                                                                                                                   List total
  ---------------------------------------------- --------------------------------- ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  3613-5p                                        Glycerolipid metabolism           4       0.012                                                                                                                                                                                                         ALDH7A1, AKR1B1, GPAM, ALDH9A1                                                                                                                          56
  Ascorbate and aldarate metabolism              3                                 0.014   ALDH7A1, UGT2B15, ALDH9A1                                                                                                                                                                                     56                                                                                                                                                      
  p53 signaling pathway                          4                                 0.037   CDK6, RRM2B, ATR, SESN3                                                                                                                                                                                       56                                                                                                                                                      
  Tryptophan metabolism                          3                                 0.069   ALDH7A1, CYP1B1, ALDH9A1                                                                                                                                                                                      56                                                                                                                                                      
  Pyruvate metabolism                            3                                 0.069   ALDH7A1, AKR1B1, ALDH9A1                                                                                                                                                                                      56                                                                                                                                                      
  Steroid hormone biosynthesis                   3                                 0.088   CYP1B1, CYP7A1, UGT2B15                                                                                                                                                                                       56                                                                                                                                                      
  2116-3p                                        Wnt signaling pathway             21      0.003                                                                                                                                                                                                         FZD8, DVL3, WNT10B, ROCK1, ROCK2, NLK, CAMK2G, CSNK1A1L, CHP2, PPP3R2, FZD7, PRKCB, WNT2, MAP3K7, SENP2, EP300, PRICKLE2, NFAT5, FRAT2, WNT7A, NFATC3   352
  B cell receptor signaling pathway              12                                0.013   MAPK1, CR2, PIK3CB, SOS2, NFAT5, CHP2, PPP3R2, VAV2, NFATC3, PIK3R1, PRKCB, BTK                                                                                                                               352                                                                                                                                                     
  p53 signaling pathway                          11                                0.017   EI24, CD82, RRM2, SERPINE1, CASP8, RCHY1, RRM2B, MDM4, PERP, CDK2, SESN3                                                                                                                                      352                                                                                                                                                     
  ErbB signaling pathway                         12                                0.036   MAPK1, CDKN1B, EREG, PIK3CB, CAMK2G, BTC, CBL, GAB1, SOS2, ELK1, PIK3R1, PRKCB                                                                                                                                352                                                                                                                                                     
  Melanogenesis                                  13                                0.039   DVL3, FZD8, ADCY1, WNT10B, ADCY2, CAMK2G, CREB1, FZD7, PRKCB, WNT2, MAPK1, EP300, WNT7A                                                                                                                       352                                                                                                                                                     
  VEGF signaling pathway                         10                                0.072   MAPK1, PIK3CB, NFAT5, CHP2, MAPKAPK3, PPP3R2, PLA2G2D, NFATC3, PIK3R1, PRKCB                                                                                                                                  352                                                                                                                                                     
  Apoptosis                                      11                                0.076   IRAK2, IRAK1, IRAK3, PRKAR2A, DFFA, PIK3CB, CASP8, CHP2, EXOG, PPP3R2, PIK3R1                                                                                                                                 352                                                                                                                                                     
  Neurotrophin signaling pathway                 14                                0.084   IRAK2, IRAK1, PIK3CB, CAMK2G, IRAK3, MAPK1, YWHAG, PRDM4, NTRK2, SOS2, GAB1, SH2B3, MAPK7, PIK3R1                                                                                                             352                                                                                                                                                     
  Prostate cancer                                11                                0.085   FGFR1, MAPK1, CDKN1B, EP300, PIK3CB, CREB1, SOS2, NKX3-1, CREB5, CDK2, PIK3R1                                                                                                                                 352                                                                                                                                                     
  Fc epsilon RI signaling pathway                10                                0.087   MAPK1, GAB2, PIK3CB, SOS2, VAV2, PRKCE, PLA2G2D, PIK3R1, PRKCB, BTK                                                                                                                                           352                                                                                                                                                     
  Long-term potentiation                         9                                 0.094   MAPK1, ADCY1, EP300, GRIN2B, CAMK2G, PPP1R1A, CHP2, PPP3R2, PRKCB                                                                                                                                             352                                                                                                                                                     
  Pathways in cancer                             30                                0.097   FGFR1, FGF16, EGLN1, WNT2, PAX8, CASP8, SOS2, NKX3-1, RALA, PIK3R1, FZD8, DVL3, WNT10B, EPAS1, PIK3CB, CBL, SKP2, FGF23, MECOM, DAPK2, CDK2, FZD7, CTNNA2, PRKCB, MAPK1, CDKN1B, EP300, ITGA6, PIAS2, WNT7A   352                                                                                                                                                     
  671-3p                                         MAPK signaling pathway            5       0.063                                                                                                                                                                                                         RASGRF1, FGF11, CACNB3, FGF1, CRK                                                                                                                       30
  30d-3p                                         Wnt signaling pathway             19      0.011                                                                                                                                                                                                         FZD8, TBL1XR1, DVL3, VANGL1, ROCK2, CAMK2G, SMAD2, FZD4, FZD6, MAP3K7, CSNK2A1, CSNK1E, CACYBP, FRAT1, MAPK8, SIAH1, PRKACB, PLCB1, APC                 340
  Prion diseases                                 7                                 0.026   C8A, EGR1, NCAM2, IL1B, HSPA5, PRKACB, PRNP                                                                                                                                                                   340                                                                                                                                                     
  Insulin signaling pathway                      16                                0.034   IRS2, PIK3CB, PHKB, PRKAB2, PRKCI, MKNK1, PPP1CB, SORBS1, SOS1, PRKAR1A, SOS2, MAPK8, PRKAA2, PRKACB, CRK, AKT3                                                                                               340                                                                                                                                                     
  Renal cell carcinoma                           10                                0.041   EPAS1, PIK3CB, SOS1, GAB1, SOS2, TGFA, EGLN1, TCEB1, CRK, AKT3                                                                                                                                                340                                                                                                                                                     
  Colorectal cancer                              11                                0.051   FZD8, DVL3, PIK3CB, SOS1, SOS2, MAPK8, SMAD2, FZD4, AKT3, FZD6, APC                                                                                                                                           340                                                                                                                                                     
  Alanine, aspartate, and glutamate metabolism   6                                 0.052   ADSS, GOT1, GFPT1, GLS, GAD1, PPAT                                                                                                                                                                            340                                                                                                                                                     
  ErbB signaling pathway                         11                                0.062   CDKN1B, ERBB4, PIK3CB, CAMK2G, SOS1, GAB1, SOS2, TGFA, MAPK8, CRK, AKT3                                                                                                                                       340                                                                                                                                                     
  Endocytosis                                    19                                0.063   SH3GL3, DNM3, FLT1, ERBB4, STAM2, VTA1, PRKCI, ARF6, HLA-B, KIT, ZFYVE20, RAB31, AP2B1, RAB-11FIP2, CHMP1B, RAB22A, RAB11B, VPS36, RNF41                                                                      340                                                                                                                                                     
  Melanogenesis                                  12                                0.064   FZD8, DVL3, GNAI3, GNAQ, CAMK2G, CREB1, CREB3L3, KIT, PRKACB, PLCB1, FZD4, FZD6                                                                                                                               340                                                                                                                                                     
  Regulation of actin cytoskeleton               21                                0.079   GNA13, FGF7, PIK3CB, ROCK2, DIAPH2, SSH2, GNA12, ITGA1, ACTN2, PPP1CB, NCKAP1, DOCK1, CHRM2, TIAM1, SOS1, SOS2, WASL, CRK, FGF2, MYLK, APC                                                                    340                                                                                                                                                     
  Neuroactive ligand--receptor interaction       24                                0.085   F2RL2, GABRG1, PTGER2, TACR3, RXFP1, GABRB3, CCKBR, OPRK1, GLRA3, LEPR, NPY2R, GRIN2A, P2RY13, PRLR, CHRM2, NMUR1, CNR1, HTR7, NPFFR2, ADRA2C, GLP2R, HTR2C, GABRQ, GABRP                                     340                                                                                                                                                     
  One carbon pool by folate                      4                                 0.086   MTHFD2, MTHFR, DHFR, MTHFD1L                                                                                                                                                                                  340                                                                                                                                                     
  30d-5p                                         Limonene and pinene degradation   3       0.033                                                                                                                                                                                                         ALDH2, LCLAT1, YOD1                                                                                                                                     106
  Ether lipid metabolism                         4                                 0.035   PLA2G12A, LCLAT1, PLA2G2C, PAFAH1B2                                                                                                                                                                           106                                                                                                                                                     
  Natural killer cell mediated cytotoxicity      7                                 0.056   CASP3, TNFRSF10B, NFAT5, PPP3CA, SH2D1B, SH3BP2, LCP2                                                                                                                                                         106                                                                                                                                                     
  ABC transporters                               4                                 0.062   ABCC9, ABCG5, ABCD2, ABCC4                                                                                                                                                                                    106                                                                                                                                                     
  Endocytosis                                    8                                 0.085   NEDD4, ACAP2, RAB11A, EEA1, NEDD4L, KIT, ARAP2, CHMP2B                                                                                                                                                        106                                                                                                                                                     
  Amyotrophic lateral sclerosis (ALS)            4                                 0.096   CASP3, MAP3K5, DERL1, PPP3CA                                                                                                                                                                                  106                                                                                                                                                     
  MAPK signaling pathway                         10                                0.099   MAP3K7, CASP3, MAP3K5, TAOK1, MAP3K2, PLA2G12A, NF1, PLA2G2C, PPP3CA, FGF20                                                                                                                                   106                                                                                                                                                     
  629-5p                                         Wnt signaling pathway             11      0.003                                                                                                                                                                                                         PLCB3, TCF7, SFRP2, VANGL2, NFAT5, LRP6, FZD3, SMAD2, MAPK10, NFATC2, MYC                                                                               120
  ErbB signaling pathway                         8                                 0.004   NRG4, GRB2, GAB1, MAPK10, MAP2K7, ABL2, MYC, AKT3                                                                                                                                                             120                                                                                                                                                     
  Colorectal cancer                              7                                 0.013   TCF7, GRB2, FZD3, SMAD2, MAPK10, MYC, AKT3                                                                                                                                                                    120                                                                                                                                                     
  Proteasome                                     5                                 0.023   PSMA2, PSMB10, PSMD13, PSMB2, PSME4                                                                                                                                                                           120                                                                                                                                                     
  Neurotrophin signaling pathway                 8                                 0.025   YWHAZ, GRB2, GAB1, MAPK10, FOXO3, MAP2K7, AKT3, CALM1                                                                                                                                                         120                                                                                                                                                     
  Endometrial cancer                             5                                 0.033   TCF7, GRB2, FOXO3, MYC, AKT3                                                                                                                                                                                  120                                                                                                                                                     
  Insulin signaling pathway                      8                                 0.038   PRKAR2A, PTPRF, TSC1, GRB2, MAPK10, INSR, AKT3, CALM1                                                                                                                                                         120                                                                                                                                                     
  Acute myeloid leukemia                         5                                 0.046   TCF7, GRB2, MYC, STAT3, AKT3                                                                                                                                                                                  120                                                                                                                                                     
  Sphingolipid metabolism                        4                                 0.062   SGMS2, KDSR, CERK, GAL3ST1                                                                                                                                                                                    120                                                                                                                                                     
  Adipocytokine signaling pathway                5                                 0.071   MAPK10, ADIPOQ, STAT3, AKT3, ACSL6                                                                                                                                                                            120                                                                                                                                                     
  Tight junction                                 7                                 0.093   CLDN8, RAB3B, MAGI2, MYH11, CLDN2, TJP2, AKT3                                                                                                                                                                 120                                                                                                                                                     
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